查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2024202

全球潛伏性結核病診斷市場：依檢測方法、風險因素及實驗室/施行地點分類－高階主管、顧問的指引、市場分析及2026-2030年預測

Latent TB Diagnostics Global Markets by Assay, By Risk Factor, and by Lab/Place. With Executive and Consultant Guides and Market Analysis and Forecasts 2026 - 2030
出版日期: | 出版商: Howe Sound Research | 英文 322 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

報告摘要：

潛伏性結核病診斷市場曾經是由少數幾家老字型大小企業生產通用產品主導的領域。但現在情況已經不同了。

結核病診斷市場持續成長，部分細分市場成長尤為強勁。了解新興領導企業和最具盈利的領域。競爭格局的核心是什麼？

本報告預測了未來五年的市場規模。雖然一些公司已經佔據了強大的市場佔有率，但創新的診斷技術有可能徹底改變市場格局。本報告詳細說明了該市場，包括其面臨的挑戰和發展前景。

本報告中的所有資料均可應要求以Excel格式提供。

利用最新數據，您可以自信地做出投資決策並評估公司估值。

目錄

第1章 市集指南

  • 情境分析
  • 高階主管和行銷負責人的指南
  • 投資分析師和管理顧問指南

第2章：引言與市場定義

  • 結核病診斷概述
  • 市場定義
  • 調查方法
  • 醫療和體外診斷行業

第3章 結核病－最新科學進展

  • 什麼是肺結核？
  • 診斷
  • 盛行率

第4章 行業概覽

  • 參與企業充滿活力的市場
    • 學術研究辦公室
    • 診斷測試開發人員
    • 醫藥和試劑供應商
    • 獨立測試機構
    • 國家研究機構
    • 醫院檢查室
    • 醫生的檢查室
    • 審計機構
    • 認證機構

第5章 市場趨勢

  • 成長促進因素
  • 成長阻礙因素
  • 診斷技術發展

第6章 結核病診斷－最新趨勢

第7章：主要企業概況

  • AID GmbH
  • Beijing Wantai
  • bioMerieux Diagnostics
  • Boditech Med, Inc
  • Endo International
  • Erythra
  • Generium
  • Glory Biotechnologies Corp.
  • Lionex Diagnostics & Therapeutics GmbH
  • Oxford Immunotec（Perkin Elmer）
  • Perkin Elmer
  • Qiagen
  • R-Biopharm AG
  • Sanofi
  • SD Biosensor
  • Serum Institute of India
  • Statens Serum Institut
  • Zhifei Longcom

第8章：全球潛伏性結核病診斷市場概述

  • 全球潛伏性結核病診斷市場概覽（按國家/地區分類）
  • 全球潛伏性結核病診斷市場概覽（依檢測類型分類）
  • 全球潛伏性結核病診斷市場概況（按風險因素分類）
  • 全球潛伏性結核病診斷市場概況（按施行地點）

第9章：潛伏性結核病診斷市場－依檢測方法分類

  • 潛伏性結核病的診斷－結核菌素皮膚試驗（TST）
  • 潛伏性結核病的診斷－γ-干擾素釋放試驗（IGRA）。
  • 潛伏性結核病的診斷 - TBST
  • 潛伏性結核病的診斷 - 其他

第10章：全球潛伏性結核病診斷市場－依風險因子分類

  • 潛伏性結核病的診斷 - HIV
  • 潛伏性結核病的診斷 -小兒科
  • 糖尿病合併潛伏性結核病的診斷
  • 潛伏性結核病的診斷—移民
  • 潛伏性結核病的診斷 - 其他

第11章 全球潛伏性結核病診斷市場－依實驗室/施行地點

  • 潛伏性結核病的診斷 - 醫院檢查室
  • 潛伏性結核病的診斷 - 門診檢查室
  • 潛伏性結核病的診斷－照護現場
  • 潛伏性結核病的診斷 - 其他

第12章附錄

表格一覽

圖表列表

簡介目錄
Product Code: IDTB 426

Report Overview:

Latent TB Diagnostics was the province of a few established companies producing a commodity product. No longer. New technologies. New niche markets.

TB Diagnostics is growing, and in some segments the growth is dramatic. Find out who the new leaders are and what areas are most lucrative. What are the basics of competition?

The report forecasts the market size out five years. Some players have already made their mark but disruptive diagnostic technology could change the playing field. Learn about this market including the issues and outlooks.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

Table of Contents

1 Market Guides

  • 1.1 Situation Analysis
  • 1.2 Guide for Executives and Marketing Staff
  • 1.3 Guide for Investment Analysts and Management Consultants

2 Introduction and Market Definition

  • 2.1 An Overview of TB Diagnostics
    • 2.1.1 The New Antigen Based TBST
  • 2.2 Market Definition
    • 2.2.1 Market Size
    • 2.2.2 Currency
    • 2.2.3 Years
    • 2.2.4 Limitations
  • 2.3 Methodology
    • 2.3.1 Methodology
    • 2.3.2 Sources
    • 2.3.3 Authors
  • 2.4 Healthcare and the IVD Industry
    • 2.4.1 Global Healthcare Spending
    • 2.4.2 Spending on Diagnostics
    • 2.4.3 Important Role of Insurance for Diagnostics

3 Tuberculosis - Current Science

  • 3.1 What is Tuberculosis?
    • 3.1.1 Causes
    • 3.1.2 Pathogenesis
    • 3.1.3 Prevention
    • 3.1.4 Treatment
  • 3.2 Diagnosis
    • 3.2.1 Active TB
    • 3.2.2 Latent TB
  • 3.3 Prevalence
    • 3.3.1 Impact of COVID on TB Prevalence

4 Industry Overview

  • 4.1 Players in a Dynamic Market
    • 4.1.1 Academic Research Lab
    • 4.1.2 Diagnostic Test Developer
    • 4.1.3 Pharmaceutical/Reagent Supplier
    • 4.1.4 Independent Testing Lab
    • 4.1.5 Public National/regional lab
    • 4.1.6 Hospital lab
    • 4.1.7 Physician Lab
    • 4.1.8 Audit Body
    • 4.1.9 Certification Body

5 Market Trends

  • 5.1 Factors Driving Growth
    • 5.1.1 Increasing Prevalence
    • 5.1.2 Increasing Diagnostic Options
    • 5.1.3 The Aging World
    • 5.1.4 Increased Health Care Spending
  • 5.2 Factors Limiting Growth
    • 5.2.1 The Cost Curve Shrinks the Market
    • 5.2.2 The Diagnostics Dillemma
    • 5.2.3 Adoption Lag and Cost Control
  • 5.3 Diagnostic Technology Development
    • 5.3.1 The Multiplex Opportunity
    • 5.3.2 Shifting Role of Physicians in Diagnosis
    • 5.3.3 Diagnostics Moves Out of the Lab
    • 5.3.4 Rapid Testing Changing Medical Practice
    • 5.3.5 The Next Five Years

6 TB Diagnostics - Recent Developments

  • 6.1 Recent Developments - Importance and How to Use This Section
    • 6.1.1 Importance of These Developments
    • 6.1.2 How to Use This Section
  • 6.2 Danaher, Cepheid Urged to Further Reduce Price of TB Tests
  • 6.3 Co-Diagnostics Submits At-Home PCR System
  • 6.4 Iinnovation in TB research by Nanopore
  • 6.5 New skin test for latent TB diagnostics
  • 6.6 Latent TB Infection Screening Recommended
  • 6.7 QIAGEN's QuantiFERON-TB Gold Plus gains new CE-marking
  • 6.8 PerkinElmer Hopes to Gain Market Share against Qiagen
  • 6.9 PBD Biotech to Develop TB Blood Test
  • 6.10 WHO Expands Assessment for TB MDx Developers
  • 6.11 Cepheid Omni POC System Falls Off Radar
  • 6.12 Non-Sputum CRISPR-Based TB Test Shows High Sensitivity
  • 6.13 NGeneBio Gets CE Mark for NGS-Based TB Assay
  • 6.14 MDx TB Assay From PBD Biotech Shows Promise
  • 6.15 Minute Molecular Dx to Launch Rapid PCR Test
  • 6.16 Qiagen Next-Gen TB Test Gains Chinese Approval
  • 6.17 FIND Invests $21M to Launch POC MDx Platforms
  • 6.18 Qiagen, DiaSorin Obtain FDA Approval for Latent TB Test
  • 6.19 Oxford Immunotec to Automate Latent TB Test
  • 6.20 LumiraDx Eyes Test Menu Expansion
  • 6.21 BioMerieux Targeting Hospitals With Desktop Latent TB Test

7 Profiles of Key Companies

  • 7.1 AID GmbH
  • 7.2 Beijing Wantai
  • 7.3 bioMerieux Diagnostics
  • 7.4 Boditech Med, Inc
  • 7.5 Endo International
  • 7.6 Erythra
  • 7.7 Generium
  • 7.8 Glory Biotechnologies Corp.
  • 7.9 Lionex Diagnostics & Therapeutics GmbH
  • 7.10 Oxford Immunotec (Perkin Elmer)
  • 7.11 Perkin Elmer
  • 7.12 Qiagen
  • 7.13 R-Biopharm AG
  • 7.14 Sanofi
  • 7.15 SD Biosensor
  • 7.16 Serum Institute of India
  • 7.17 Statens Serum Institut
  • 7.18 Zhifei Longcom

8 Latent TB Global Diagnostic Markets Overview

  • 8.1 Latent TB Diagnostics - Global Market Overview by Country
    • 8.1.1 Table - Global Market by Country
    • 8.1.2 Chart - Global Market by Country
  • 8.2 Global Latent TB Diagnostics Markets Overview by Assay
    • 8.2.1 Table - Global Market by Assay
    • 8.2.2 Chart - Global Market by Assay - Segments Growth
    • 8.2.3 Chart - Global Market by Assay - Share by Year
    • 8.2.4 Chart - Global Market by Assay
    • 8.2.5 Chart - Global Market by Assay - Base Year
    • 8.2.6 Chart - Global Market by Assay - Final Year
  • 8.3 Global Latent TB Diagnostics Markets Overview by Risk Factor
    • 8.3.1 Table - Global Market by Risk Factor
    • 8.3.2 Chart - Global Market by Risk Factor - Segments Growth
    • 8.3.3 Chart - Global Market by Risk Factor - Share by Year
    • 8.3.4 Chart - Global Market by Risk Factor
    • 8.3.5 Chart - Global Market by Risk Factor - Base Year
    • 8.3.6 Chart - Global Market by Risk Factor - Final Year
  • 8.4 Global Latent TB Diagnostics Markets Overview by Lab
    • 8.4.1 Table - Global Market by Lab
    • 8.4.2 Chart - Global Market by Lab - Segments Growth
    • 8.4.3 Chart - Global Market by Lab - Share by Year
    • 8.4.4 Chart - Global Market by Lab
    • 8.4.5 Chart - Global Market by Lab - Base Year
    • 8.4.6 Chart - Global Market by Lab - Final Year

9 Latent TB Diagnostic Market - by Assay

  • 9.1 Latent TB Diagnostic - TST
    • 9.1.1 Table Latent TB Diagnostic TST - by Country
    • 9.1.2 Chart - Latent TB Diagnostic TST Growth
  • 9.2 Latent TB Diagnostic - IGRA
    • 9.2.1 Table Latent TB Diagnostic IGRA - by Country
    • 9.2.2 Chart - Latent TB Diagnostic IGRA Growth
  • 9.3 Latent TB Diagnostic - TBST
    • 9.3.1 Table Latent TB Diagnostic TBST - by Country
    • 9.3.2 Chart - Latent TB Diagnostic - TBST Growth
  • 9.4 Latent TB Diagnostic - Other
    • 9.4.1 Table Latent TB Diagnostic Other - by Country
    • 9.4.2 Chart - Latent TB Diagnostic - Other Growth

10 Global Latent TB Diagnostics Markets - By Risk Factor

  • 10.1 Latent TB Diagnostic - HIV
    • 10.1.1 Table Latent TB Diagnostic HIV - by Country
    • 10.1.2 Chart - Latent TB Diagnostic HIV Growth
  • 10.2 Latent TB Diagnostic - Pediatric
    • 10.2.1 Table Latent TB Diagnostic Pediatric - by Country
    • 10.2.2 Chart - Latent TB Diagnostic Pediatric
  • 10.3 Latent TB Diagnostic - Diabetes
    • 10.3.1 Table Latent TB Diagnostic Diabetes - by Country
    • 10.3.2 Chart - Latent TB Diagnostic - Diabetes Growth
  • 10.4 Latent TB Diagnostic - Immigration
    • 10.4.1 Table Latent TB Diagnostic Immigration - by Country
    • 10.4.2 Chart - Latent TB Diagnostic - Immigration Growth
  • 10.5 Latent TB Diagnostic - Other Risk Factor
    • 10.5.1 Table Latent TB Diagnostic Other Risk Factor - by Country
    • 10.5.2 Chart - Latent TB Diagnostic - Other Risk Factor Growth

11 Global Latent TB Diagnostics Markets - By Lab/Place

  • 11.1 Latent TB Diagnostic - Hospital Lab
    • 11.1.1 Table Latent TB Diagnostic Hospital Lab - by Country
    • 11.1.2 Chart - Latent TB Diagnostic Hospital Lab Growth
  • 11.2 Latent TB Diagnostic - Outpatient Lab
    • 11.2.1 Table Latent TB Diagnostic Outpatient Lab - by Country
    • 11.2.2 Chart - Latent TB Diagnostic Outpatient Lab Growth
  • 11.3 Latent TB Diagnostic - Point of Care
    • 11.3.1 Table Latent TB Diagnostic Point of Care - by Country
    • 11.3.2 Chart - Latent TB Diagnostic Point of Care
  • 11.4 Latent TB Diagnostic - Other Place
    • 11.4.1 Table Latent TB Diagnostic Other Place - by Country
    • 11.4.2 Chart - Latent TB Diagnostic Other Place

12 Appendices

  • 12.1 United States Medicare System: Clinical Laboratory Fees Schedule

Table of Tables

  • Table 1 - TST vs IGRA
  • Table 2 Market Players by Type
  • Table 3 Five Factors Driving Growth
  • Table 4 Three Factors Limiting Growth
  • Table 5 - Global Latent TB Diagnostics Market by Country/Region
  • Table 6 Global Market by Assay
  • Table 7 Global Market by Risk Factor
  • Table 8 Global Market by Lab
  • Table 9 Latent TB Diagnostic TST by Country
  • Table 10 Latent TB Diagnostic IGRA by Country
  • Table 11 Latent TB Diagnostic TBST by Country
  • Table 12 Latent TB Diagnostic Other by Country
  • Table 13 Latent TB Diagnostic HIV by Country
  • Table 14 Latent TB Diagnostic Pediatric by Country
  • Table 15 Latent TB Diagnostic Diabetes by Country
  • Table 16 Latent TB Diagnostic Immigration by Country
  • Table 17 Latent TB Diagnostic Other Risk Factor by Country
  • Table 18 Latent TB Diagnostic Hospital Lab by Country
  • Table 19 Latent TB Diagnostic Outpatient Lab by Country
  • Table 20 Latent TB Diagnostic Point of Care by Country
  • Table 21 Latent TB Diagnostic Other Place by Country
  • Table 22 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Global Prevalence of TB - 2019
  • Figure 2 Global Healthcare Spending Map
  • Figure 3 The Lab Test Pie - Wholesale and Retail
  • Figure 4 Percentage of World Population Over 65
  • Figure 5 Growth in Health Care Spending Developing World
  • Figure 6 Comparing The New Diagnostics and Traditional Testing
  • Figure 7 Growth rates of Latent TB Diagnostics
  • Figure 8 Global Market Share Chart
  • Figure 9 Latent TB Diagnostics Market Segment Shift Base vs Final year
  • Figure 10 Latent TB Diagnostics Market by Assay Base Year
  • Figure 11 Latent TB Diagnostics Market by Assay Final Year
  • Figure 12 Latent TB Diagnostics Market Segment Shift Base vs Final year
  • Figure 13 Latent TB Diagnostics Market by Risk Factor Base Year
  • Figure 14 Latent TB Diagnostics Market by Risk Factor Final Year
  • Figure 15 Latent TB Diagnostics Market Segment Shift Base vs Final year
  • Figure 16 Latent TB Diagnostics Market by Lab Base Year
  • Figure 17 Latent TB Diagnostics Market by Lab Final Year
  • Figure 18 Latent TB Diagnostic TST Growth
  • Figure 19 LATENT TB Diagnostics Syndromic POC Panel Growth
  • Figure 20 Latent TB Diagnostic TBST Growth
  • Figure 21 Latent TB Diagnostic Other Growth
  • Figure 22 Latent TB Diagnostic HIV Growth
  • Figure 23 LATENT TB Diagnostics Pediatric
  • Figure 24 Latent TB Diagnostic Diabetes Growth
  • Figure 25 Latent TB Diagnostic Immigration Growth
  • Figure 26 Latent TB Diagnostic Other Risk Factor Growth
  • Figure 27 Latent TB Diagnostic Hospital Lab Growth
  • Figure 28 Latent TB Diagnostic Outpatient Lab Growth
  • Figure 29 LATENT TB Diagnostics Point of Care
  • Figure 30 LATENT TB Diagnostics Other Place